Autologous mesenchymal stem cell therapy - Pharmicell

Drug Profile

Autologous mesenchymal stem cell therapy - Pharmicell

Alternative Names: Cellgram-ED; Cerecellgram-spine; Hearticellgram-AMI; Immunocellgram; Impocellgram; Livercellgram; Lungcellgram; MSC 1 - FCB Pharmicell; MSC 2 - FCB Pharmicell

Latest Information Update: 28 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FCB-Pharmicell
  • Developer Asan Medical Center; Nonindustrial source; Pharmicell; Samsung Medical Center; Yonsei University Health System
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase III Stroke
  • Phase II/III Spinal cord injuries
  • Phase II Adult respiratory distress syndrome; Liver cirrhosis
  • Phase I/II Graft-versus-host disease; Parkinson's disease; Renal transplant rejection
  • Phase I Erectile dysfunction
  • Clinical Phase Unknown Brain injuries; Cerebral haemorrhage; Solid tumours
  • Preclinical Pulmonary fibrosis

Most Recent Events

  • 01 Mar 2016 Pharmicell completes a phase II trial in Cirrhosis in South Korea (Intra-arterial) (NCT01875081)
  • 01 Jul 2015 Phase-I clinical trials in Erectile dysfunction in South Korea (Intracavernous) (NCT02344849)
  • 25 Jun 2015 Pharmicell plans a phase I trial for Peripheral arterial disorders (in patients with critical limb ischaemia) in South Korea (NCT02477540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top